Atezolizumab for untreated PD-L1 positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (CDF review TA492): a single technology appraisal
Report published in 2021 by
Keith Cooper 
,
Karen Pickett,
Inês Ribeiro,
David Alexander Scott,
Jonathan Shepherd
,
Karen Pickett,
Inês Ribeiro,
David Alexander Scott,
Jonathan Shepherd
